Squibb Company (NYSE:BMY) and The
University of Texas MD Anderson Cancer Center today announced a
novel clinical research collaboration to evaluate multiple
immunotherapies, including Opdivo (nivolumab), Yervoy
(ipilimumab) and three early-stage clinical immuno-oncology assets from
Bristol-Myers Squibb, as potential treatment options for acute and
chronic leukemia as well as other hematologic malignancies.
for Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia and Hematologic Malignancies investment picks